$37.43
0.21% yesterday
NYSE, Dec 24, 07:00 pm CET
ISIN
US6031701013
Symbol
MLYS

Mineralys Therapeutics Stock price

$37.43
-5.17 12.14% 1M
+23.29 164.71% 6M
+25.12 204.06% YTD
+24.63 192.42% 1Y
+18.99 102.98% 3Y
+18.99 102.98% 5Y
+18.99 102.98% 10Y
+18.99 102.98% 20Y
NYSE, Closing price Wed, Dec 24 2025
+0.08 0.21%
ISIN
US6031701013
Symbol
MLYS
Industry

Key metrics

Basic
Market capitalization
$3.0b
Enterprise Value
$2.4b
Net debt
positive
Cash
$593.6m
Shares outstanding
79.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
5.1
Financial Health
Equity Ratio
92.9%
Return on Equity
-93.0%
ROCE
-31.9%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-184.0m | $-196.5m
EBIT
$-184.1m | $-185.2m
Net Income
$-171.4m | $-202.2m
Free Cash Flow
$-171.4m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-9.5% | -2.1%
EBIT
-9.5% | 3.8%
Net Income
-11.8% | -13.7%
Free Cash Flow
-33.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-2.4
FCF per Share
$-2.2
Short interest
11.7%
Employees
51
Rev per Employee
$0.0
Show more

Is Mineralys Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Mineralys Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Mineralys Therapeutics forecast:

13x Buy
87%
2x Hold
13%

Analyst Opinions

15 Analysts have issued a Mineralys Therapeutics forecast:

Buy
87%
Hold
13%

Financial data from Mineralys Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 32 32
55% 55%
-
- Research and Development Expense 152 152
3% 3%
-
-184 -184
9% 9%
-
- Depreciation and Amortization 0.06 0.06
100% 100%
-
EBIT (Operating Income) EBIT -184 -184
10% 10%
-
Net Profit -171 -171
12% 12%
-

In millions USD.

Don't miss a Thing! We will send you all news about Mineralys Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Mineralys Therapeutics Stock News

Positive
The Motley Fool
2 days ago
New York City-based Suvretta Capital Management increased its MLYS position by 387,641 shares in the third quarter. The overall position value increased by $57.25 million from the previous period.
Neutral
GlobeNewsWire
13 days ago
– Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful of 2025 by JAMA editors –
Positive
The Motley Fool
28 days ago
New York City-based Findell Capital Management added 250,000 shares of MLYS, valued at $9.5 million, in the third quarter. The purchase marked a new position for Findell, which reported holding no shares of MLYS in the previous quarter.
More Mineralys Therapeutics News

Company Profile

Mineralys Therapeutics, Inc. s a clinical-stage biopharmaceutical company engaged in developing medicines to target disease, driven by abnormally elevated aldosterone. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Head office United States
CEO Jon Congleton
Employees 51
Founded 2019
Website mineralystx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today